Billiontoone (NASDAQ:BLLN) Now Covered by Guggenheim

Analysts at Guggenheim started coverage on shares of Billiontoone (NASDAQ:BLLN) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $120.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 26.48% from the stock’s previous close.

Several other research firms have also commented on BLLN. William Blair started coverage on shares of Billiontoone in a research report on Monday, December 1st. They set an “outperform” rating for the company. Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus began coverage on Billiontoone in a research report on Monday, December 1st. They issued a “buy” rating and a $145.00 price target for the company. Wells Fargo & Company began coverage on Billiontoone in a research note on Monday, December 1st. They set an “equal weight” rating and a $110.00 price objective on the stock. Finally, Piper Sandler restated an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $135.29.

Billiontoone Stock Performance

NASDAQ:BLLN opened at $94.88 on Tuesday. The company has a market capitalization of $4.34 billion and a price-to-earnings ratio of 948.80. Billiontoone has a 1 year low of $80.51 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Tuesday, December 9th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.06). The firm had revenue of $83.52 million during the quarter, compared to analysts’ expectations of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.